AN2 Therapeutics Announces Poster Presentation Highlighting M. Abscessus Data at 2025 Colorado Mycobacteria Conference

About this update from An2 Therapeutics, Inc.

Epetraborole’s potent activity against M. abscessus supports further investigation as a potential therapy for disease with an estimated all-cause mortality of 45% MENLO PARK, Calif., May 29, 2025 --( BUSINESS WIRE )--AN2 Therapeutics, Inc. (Nasdaq: ANTX), a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics derived from its boron chemistry platform, today announced that the company will present a poster highlighting the preclinical activity of epetraborole against M. abscessus on Thursday, May 29, 2025 at the Nontuberculous Mycobacteria Conference to be held May 27-30, 2025 at Colorado State University. It is estimated that M. abscessus affects approximately 50,000 patients in the U.S., Japan and Europe. Details of the poster presentation are as follows: Abstract title: Epetraborole, a Potential Oral Agent for Mycobacterium abscessus Lung Disease Date and Time: May 29, 2025; 3:30 p.m. - 5:30 p.m. CT Poster/Abstract number: 74 Presenting Author : MRK Alley, Ph.D. A copy of the poster will be available on the AN2 Therapeutics website at the following link simultaneously with the poster session Development Pipeline | AN2 Therapeutics . About AN2 Therapeutics, Inc. AN2 Therapeutics, Inc. is a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics derived from its boron chemistry platform. AN2 has a pipeline of boron-based compounds in development for Chagas disease, melioidosis, and NTM lung disease caused by M. abscessus, along with early-stage programs focused on targets in infectious diseases and oncology. We are committed to delivering high-impact drugs to patients that address critical unmet needs and improve health outcomes. For more information, please visit our website at www.an2therapeutics.com . View source version on businesswire.com: https://www.businesswire.com/news/home/20250529160056/en/ Contacts COMPANY CONTACT: Lucy O. Day Chief Financial Officer [email protected] INVESTOR AND MEDIA CONTACT: Anne Bowdidge [email protected]

View stock analysis, news, and events for An2 Therapeutics, Inc.